NRX Pharmaceuticals, Inc. NRXP 深 沪
已收盘 08-14 16:00:00 美东时间
3.27
-0.070
-2.10%
华盛通- 最 高3.40
- 今 开3.37
- 成交量 112.87万股
- 最 低 3.155
- 昨 收 3.34
- 总市值 1.37亿
- 52周最高 5.055
- 市盈率 静 --
- 换手率 2.69%
- 52周最低 1.62
- 委 比 10.34%
- 总股本 4194.33万
- 历史最高 769.90
- 量 比 0.51
- 振 幅 7.34%
- 历史最低 1.58
- 每 手 1
- 风险率 0.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10
BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.
08-08 02:19
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
NRx Pharmaceuticals will host a conference call on August 10, 2026, at 8:30 a.m. ET to discuss the FDA's review of its ANDA for preservative-free ketamine. Participants include Jonathan Javitt, MD, MPH, CEO; Glenn Tyson, CCO; and Chaim Hurvitz, a former Teva executive. The call will cover regulatory and commercial plans. A live webcast will be available on the company’s website, with a replay afterward. NRx is developing therapeutics for CNS diso...
08-07 20:01
NRx Pharma Announces FDA Approval Of Intermediate Population Expanded Access Protocol For Use Of NRX-101, Fixed Dose Combination Of DCS And Lurasidone For Augmentation Of Accelerated TMS
D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TMS) in remission from depression and suicidality in several published clinical studies. NRx Pharmaceuticals is developing NRX-101, a fixed dose combination of DCS+lurasidone for the augmentation of TMS...
06-22 19:14
NRx Pharmaceuticals Prices $20M Public Offering Of 5,714,286 Shares Of Common Stock At A Price Of $3.50/Share To Fund Working Capital And Growth Plans
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering (the "Offering") of 5,714,286
06-03 20:20
美股夜盘 | Xos, Inc.涨174.44%，Rubico Inc.涨38.00%
NRX Pharmaceuticals, Inc.涨-17.53%；GMEX ROBOTICS CORPORATION Class A涨-8.59%；鼎信控股涨-8.08%
06-03 08:05
NRx Pharma's HOPE Unit Deploys Zeta Surgical's FDA‑Cleared TMS Navigation System At West Palm Beach Clinic To Deliver Image‑Guided Therapy For Major Depressive Disorder And Other Neurological Conditions
Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological
05-27 19:23
美股牛股 | SpaceX IPO“磁场效应”持续发酵！太空概念股MNTS、Redwire飙升；BRAI大涨74%
SpaceX IPO“磁场效应”持续发酵！太空概念股MNTS飙涨109%，Redwire大涨26%；BRAI大涨74%，与英国交换基础设施提供商达成战略合作>>
05-27 19:19
NRx Pharma Targets FDA Approvals, Expands Clinics And Advances PTSD Drug Pipeline In 2026
Key highlights from the first quarter of operations under the expanded management team include the following:Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, with favorable
05-18 19:12
NRX Pharmaceuticals Q1 EPS $(0.04) Up From $(0.34) YoY, Sales $1.068M
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.04) per share. This is a 88.24 percent increase over losses of $(0.34) per share from the same period last year. The company reported $1.068 million in
05-16 05:55
